Business news

    Radiopharm Theranostics (ASX:RAD) begins Phase 1 trial of RAD 204 for non-small cell lung cancer

    Article Image

    Radiopharm Theranostics has initiated a Phase 1 clinical trial for RAD 204, targeting PD-L1-positive non-small cell lung cancer.

    Conducted at multiple Australian sites, including Wollongong Hospital in New South Wales, Princess Alexandra Hospital in Queensland, and Hollywood Private Hospital in Western Australia, RAD 204 aims to assess safety and preliminary efficacy in patients with metastatic NSCLC.

    Radiopharm's previous Phase 1 diagnostic study demonstrated positive results, supporting its potential as a new treatment option for advanced NSCLC.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa